

SUPERVISORS

Prof. Jimmy Van den Eynden

Dept. of Human Structure and Repair (GE38)
Ghent University, Belgium

Prof. Ruth Palmer

Dept. of Medical Biochemistry and Cell Biology
University of Gothenburg, Sweden

EXAMINATION COMMITTEE

Prof. Katleen De Preter (chair)

Dept. of Biomolecular Medicine (GE31)
Ghent University, Belgium

Prof. Kaat Durinck

Dept. of Biomolecular Medicine (GE31)
Ghent University, Belgium

Prof. Celine Everaert

Dept. of Biomolecular Medicine (GE31)
Ghent University, Belgium

Prof. Vanessa Vermeirssen

Dept. of Biomolecular Medicine (GE31), Dept. of
Biomedical Molecular Biology (WE14)
Ghent University, Belgium

Prof. Kathleen Marchal

Dept. of Information Technology (EA05), Dept. of
Plant Biotechnology and Bioinformatics (WE09)
Ghent University, Belgium

Prof. Bram De Wilde

Dept. of Biomolecular Medicine (GE31), Dept. of
Internal Diseases and Pediatrics (GE35)
Ghent University, Belgium

Prof. Sven Nelander

Dept. of Immunology
Uppsala University, Sweden

CONTACT

Department of Human Structure and
Repair
cgg.ugent.be
Computational Cancer Genomics and
Tumor Evolution Lab
jonatan.gabre@ugent.be

PUBLICATIONS

*Preclinical exploration of the DNA damage
response pathway using the interactive
neuroblastoma cell line explorer CLEAN
NAR Cancer, 2024

<https://doi.org/10.1093%2Fncrncan%2Fzcad062>

ALK signaling primes the DNA damage
response sensitizing ALK-driven
neuroblastoma to therapeutic ATR
inhibition

PNAS, 2023

<https://doi.org/10.1073/pnas.2315242121>

ALK fusion NSCLC oncogenes promote
survival and inhibit NK cell responses via
SERPINB4 expression

PNAS, 2023

<https://doi.org/10.1073/pnas.2216479120>

Novel human-derived EML4-ALK fusion cell
lines identify ribonucleotide reductase
RRM2 as a target of activated ALK in
NSCLC

Lung Cancer, 2022

<https://doi.org/10.1016/j.lungcan.2022.07.010>

ATR inhibition enables complete tumour
regression in ALK-driven NB mouse models

Nature Communications, 2021

<https://doi.org/10.1038/s41467-021-27057-2>

*Loss of RET Promotes Mesenchymal
Identity in Neuroblastoma Cells

Cancers, 2021

<https://doi.org/10.3390/cancers13081909>

*The coelomic epithelium transcriptome
from a clonal sea star, *Coscinasterias
muricata*

Marine Genomics, 2015

<https://doi.org/10.1016/j.margen.2015.07.010>

* = first author

*Computational
approaches to facilitate
the identification of
novel therapeutic
targets in
neuroblastoma and
other ALK-driven
cancers*

GHENT UNIVERSITY,
FACULTY OF MEDICINE AND
HEALTH SCIENCES, 2024

**JONATAN L.
GABRE**

Thesis submitted to fulfil the
requirements for the degree of
“Doctor in Health Sciences”.





Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells

OBJECTIVES

Neuroblastoma (NB) is one of the deadliest childhood cancers, accounting for about 15% of all pediatric cancer-related deaths. Tumors develop during early development and arise in the sympathetic nervous system and the adrenal gland.



Anaplastic Lymphoma Kinase (ALK) is gene that is mutated in around 10% of all NB tumors and, together with other factors like MYCN Amplification (MNA), drives this cancer. Despite the availability of potent ALK inhibitors, the clinical outcomes for patients harboring oncogenic ALK mutations remain poor. To improve the prognosis for these individuals, this PhD aimed to identify targets for combinatorial treatment with ALK inhibitors, as well as to further our understanding of this protein and its interactors.

In the first part of this PhD, we explored REarranged during Transfection (RET). This protein has been suggested as a potential target for combination with ALK inhibition. It is highly expressed in NB and is critical during development. It has also been identified as a driver in various other cancers, such as lung, breast, and prostate cancers.


In our study, we uncovered a previously unknown mechanistic relationship between ALK and RET—ALK and RET appear to be co-regulated in NB cells.

We further investigated the effects of disrupting RET activity. By analyzing global gene expression in NB cells where RET was disabled, we observed a phenotypic shift from a state typically associated with better patient prognosis (adrenergic) to a less proliferative but more therapeutically resistant state (mesenchymal).

DISRUPTING RET LEADS TO A SHIFT FROM AN ADRENERGIC (ADRN) TO A MESENCHYMAL (MES) CELLSTATE.



Preclinical exploration of the DNA Damage Response pathway using the interactive neuroblastoma cell line explorer CLEAN



CLEAN IS AN INTERACTIVE WEB APPLICATION FOR EXPLORATION OF HIGH THROUGHPUT NB CELL LINE DATA: [HTTPS://CCGG.UGENT.BE/SHINY/CLEAN/](https://ccgg.ugent.be/shiny/clean/)

For the study mentioned above, as well as every other study conducted during this PhD, we relied on high-throughput data. Each study generated thousands of data points, many of which remain unaddressed in the original analyses. Additionally, accessing and interpreting this information post-publication often requires bioinformatics expertise, effectively excluding a significant portion of the scientific community from engaging with these datasets. To bridge this gap, we developed the Cell Line Explorer App of Neuroblastoma (CLEAN), an interactive web application that enables users, regardless of computational background, to explore all published preclinical NB cell line data to generate new findings. To illustrate how CLEAN can be used, we demonstrate two use cases focusing on exploration of the DDR.

